{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-25-000096","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.771772+00:00","generated_at":"2026-05-17T02:30:07.127013+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intensity Therapeutics shareholders approve reverse stock split ratio of 1:5 to 1:30","bullets":["Reverse split proposal passed with 18,333,570 For, 4,508,502 Against, 27,490 Abstain.","Adjournment proposal also approved: 18,869,741 For, 3,893,779 Against, 106,042 Abstain.","Quorum of 22,869,562 shares (46.61% of outstanding common stock) was present at the 10/22/2025 Special Meeting.","Board may set the exact ratio within 1:5 to 1:30 range or abandon the split entirely."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-25-000096","json":"https://secwatch.observer/filing/0001567264-25-000096.json","markdown":"https://secwatch.observer/filing/0001567264-25-000096.md","text":"https://secwatch.observer/filing/0001567264-25-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000096/0001567264-25-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000096/intensity-20251022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:30:07.127013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}